

Final Agenda

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

Wednesday, June 25, 2025

10:00 Opening Remarks

Dr. Martin Kulldorff (ACIP Chair)

10:15 Welcome and Roll Call

Dr. Mina Zadeh (ACIP Executive Secretary, CDC)

10:35 Update on Work Groups

Dr. Martin Kulldorff (ACIP Chair)

11:00 COVID-19 Vaccines

Introduction

Dr. Adam MacNeil (CDC/NCIRD)

COVID-19 epidemiology

Dr. Adam MacNeil (CDC/NCIRD)

COVID-19 vaccine effectiveness update

Dr. Adam MacNeil (CDC/NCIRD)

COVID-19 safety update

Dr. Sarah Meyer (CDC/NCEZID)

COVID-19 vaccine coverage and implementation

Dr. Georgina Peacock (CDC/NCIRD)

Evidence to recommendations (partial)

Dr. Adam MacNeil (CDC/NCIRD)

1:00

Lunch

1:30 Agency Updates

CDC, CMS, FDA, HRSA, IHS, NIH

2:00 RSV Vaccines- Maternal/Pediatric

Introduction

Dr. Adam MacNeil (CDC/NCIRD)

Updates on uptake of maternal vaccine and nirsevimab

Dr. Georgina Peacock (CDC/NCIRD)

Effectiveness and impact of RSV prevention products in infants during the 2024-2025 season

Dr. Adam MacNeil (CDC/NCIRD)

Updates on safety of maternal vaccine and nirsevimab

Dr. Malini DeSilva (HealthPartners),

Dr. Matthew Daley (Kaiser Permanente Colorado)

Updates and summary of the Evidence to Recommendation

Dr. Adam MacNeil (CDC/NCIRD)

Framework for clesrovimab

Updates on clinical considerations for clesrovimab

Dr. Adam MacNeil (CDC/NCIRD)

Proposed Recommendations

Dr. Adam MacNeil (CDC/NCIRD)

Updates to RSV vaccines VFC resolution

Dr. Georgina Peacock (CDC/NCIRD)

4:00

Break

4:15 Public Comment

5:00 Votes

RSV Vaccines- Pediatric

Dr. Adam MacNeil (CDC/NCIRD)

RSV Vaccines- VFC

Dr. Georgina Peacock (CDC/NCIRD)

5:30 Adjourn

Final Agenda

Thursday, June 26, 2025

8:00 Welcome and Roll Call

Dr. Mina Zadeh (ACIP Executive Secretary, CDC)

8:15 Influenza Vaccines

Introduction

Dr. Vivien Dugan (CDC/NCIRD)

Flublok in older children and adolescents: immunogenicity and safety

Dr. Pedro Folegatti (Sanofi Pasteur)

Estimates of influenza burden and burden averted through vaccination

Dr. Vivien Dugan (CDC/NCIRD)

Proposed recommendations for 2025-26

Dr. Vivien Dugan (CDC/NCIRD)

Presentation regarding thimerosal in vaccines

Lyn Redwood, RN, MSN

Proposed recommendations regarding thimerosal containing influenza vaccine

Dr. Martin Kulldorff (ACIP Chair)

10:15

Break

10:30 Chikungunya Vaccines

Introduction

Dr. Lyle Petersen (CDC/NCEZID)

EtR (partial) for use of live attenuated and virus-like particle chikungunya

Dr. Lyle Petersen (CDC/NCEZID)

vaccines in U.S territories

Safety update on live attenuated chikungunya vaccine and use among older persons

Dr. Lyle Petersen (CDC/NCEZID)

10:45 Anthrax Vaccine

Dr. Brendan Jackson (CDC/NCEZID)

10:50 MMRV Vaccine

Presentation on MMRV vaccine in children under 4 years of age

Dr. Martin Kulldorff (ACIP Chair)

Proposed recommendations regarding MMRV in children under 4 years of age

Dr. Martin Kulldorff (ACIP Chair)

11:20

Break

11:30 Public Comment

12:15

Break

12:30 Votes

Influenza Vaccines

Dr. Vivien Dugan

Thimerosal containing influenza vaccine recommendations

Dr. Martin Kulldorff (ACIP Chair)

1:00 Adjourn

Acronyms

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare & Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
MMRV	Measles, Mumps, Rubella, Varicella Vaccine
NCIRD	National Center for Immunization & Respiratory Diseases
NCEZID	National Center for Emerging and Zoonotic Diseases
NIH	National Institutes of Health
RSV	Respiratory Syncytial Virus
VFC	Vaccines for Children